b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30043413</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>06</Month>\n            <Day>13</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>06</Month>\n            <Day>13</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Electronic">1875-9114</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>38</Volume>\n                    <Issue>9</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>09</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Pharmacotherapy</Title>\n                <ISOAbbreviation>Pharmacotherapy</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>FDA Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug Approvals.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>967-980</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1002/phar.2167</ELocationID>\n            <Abstract>\n                <AbstractText>The United States Food and Drug Administration (FDA) has created approval pathways and designations to accelerate access to medications indicated for serious or life-threatening conditions with limited treatment options. Implemented in 2012, the most recent of these is the breakthrough therapy designation (BTD). The purpose of this article was to review the evidence surrounding approval of medications with nononcology indications approved with the BTD designation from 2012 to 2016. Fifteen medications were identified for eight conditions, ranging from conditions that are relatively common, such as chronic hepatitis C infection, to those that are extremely rare, such as lysosomal acid lipase deficiency. The quality of evidence behind these approvals was highly heterogeneous. Much remains unknown about the safety and efficacy of many agents approved through the BTD. Health care professionals should be aware of these limitations to better educate patients and other providers appropriately.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 2018 Pharmacotherapy Publications, Inc.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Herink</LastName>\n                    <ForeName>Megan C</ForeName>\n                    <Initials>MC</Initials>\n                    <Identifier Source="ORCID">0000-0001-6402-0260</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacy Practice, Oregon State University/Oregon Health &amp; Science University College of Pharmacy, Portland, Oregon.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Irwin</LastName>\n                    <ForeName>Adriane N</ForeName>\n                    <Initials>AN</Initials>\n                    <Identifier Source="ORCID">0000-0002-2086-4493</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacy Practice, Oregon State University/Oregon Health &amp; Science University College of Pharmacy, Corvallis, Oregon.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zumach</LastName>\n                    <ForeName>Gregory M</ForeName>\n                    <Initials>GM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacy Practice, Oregon State University/Oregon Health &amp; Science University College of Pharmacy, Corvallis, Oregon.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Pharmacotherapy</MedlineTA>\n            <NlmUniqueID>8111305</NlmUniqueID>\n            <ISSNLinking>0277-0008</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName>\n                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017277" MajorTopicYN="Y">Drug Approval</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D035583" MajorTopicYN="N">Rare Diseases</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName>\n                <QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>\n                <QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">\nBTD\n</Keyword>\n            <Keyword MajorTopicYN="Y">\nFDA\n</Keyword>\n            <Keyword MajorTopicYN="Y">U.S. Food and Drug Administration</Keyword>\n            <Keyword MajorTopicYN="Y">accelerated approval</Keyword>\n            <Keyword MajorTopicYN="Y">breakthrough therapy designation</Keyword>\n            <Keyword MajorTopicYN="Y">drug safety</Keyword>\n            <Keyword MajorTopicYN="Y">rare diseases</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>7</Month>\n                <Day>26</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>14</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>7</Month>\n                <Day>26</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30043413</ArticleId>\n            <ArticleId IdType="doi">10.1002/phar.2167</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'